News Focus
News Focus
Followers 143
Posts 24055
Boards Moderated 0
Alias Born 06/13/2011

Re: Number sleven post# 263743

Tuesday, 04/07/2020 9:07:37 PM

Tuesday, April 07, 2020 9:07:37 PM

Post# of 448124
N. I have been going over this with poster HamPanky ...chk his posts re Teva .

I've been arguing that Teva already has an established " fish oil " API and sales structure in place ...selling generic Lovaza. His DD has revealed several others in the G Lovaza space ..O3 Ethyl Esters .

Teva already has a royalty payment arrangement with AMRN via their settlement agreement . If AMRN was to lose the appeal trial I surmise it would be in Amarins interest to assign its API supply agreements to Teva ...because at least they still get the royalty payment .

Rather than having a fragmented market between several generic Co's ...AMRN would help Teva dominate ..and get royalties . Just looking at all possibilities ...still want AMRN to win the appeal obviously

Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News